Valuation : Quest PharmaTech Inc.

Market Cap 3.38M 2.44M 2.11M 1.99M 1.81M 231M 3.41M 23.51M 9.13M 118M 9.18M 8.98M 388M P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 4.37M 3.16M 2.72M 2.56M 2.34M 298M 4.4M 30.37M 11.79M 152M 11.85M 11.59M 501M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
3 months-42.86%
6 months-33.33%
Current year-42.86%
1 week 0.02
Extreme 0.02
0.02
1 month 0.02
Extreme 0.02
0.02
Current year 0.02
Extreme 0.02
0.04
1 year 0.02
Extreme 0.02
0.05
3 years 0.02
Extreme 0.015
0.07
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 17/06/2004
Director of Finance/CFO - 01/01/2005
Director TitleAgeSince
Director/Board Member - 17/06/2004
Chairman - 05/07/2021
Director/Board Member - 05/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
12/12/25 OtherCompany 0 0% -
21/10/25 Other

Chief Executive Officer

1,000,000 0.5913%
21/10/25 Other

Chief Executive Officer

300,000 0.1774%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-50.00%-71.43% 2.43M
+0.97%-1.75%+2.17%+18.46% 49.74B
-0.30%-2.88%+429.29%+521.04% 44.98B
+2.13%+0.89%+43.59%+19.44% 42.52B
+0.87%-3.73%+8.96%+76.62% 40.78B
-0.90%-1.74%+15.20%+48.44% 32.89B
+2.71%+6.82% - - 17.09B
+1.68%-4.20%+25.28%+123.70% 16.28B
+1.70%-1.75%+12.00%+28.50% 14.4B
+3.34%-1.13%+80.94%+42.82% 13.48B
Average +1.22%-2.18%+63.05%+89.73% 27.22B
Weighted average by Cap. +1.01%-2.25%+93.36%+128.99%

Financials

2025 2026
Net sales - -
Net income -1.8M -1.3M -1.12M -1.06M -964K -123M -1.81M -12.52M -4.86M -62.85M -4.89M -4.78M -206M 5M 3.61M 3.12M 2.93M 2.67M 341M 5.04M 34.75M 13.49M 174M 13.56M 13.26M 573M
Net Debt 795K 574K 495K 467K 425K 54.26M 801K 5.53M 2.14M 27.74M 2.16M 2.11M 91.12M 986K 712K 614K 579K 527K 67.27M 993K 6.85M 2.66M 34.4M 2.67M 2.62M 113M
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume